a Department of Biotechnology , Indian Institute of Technology, Madras (IIT M) , Chennai , India.
b Department of Human Genetics , College of Biomedical Sciences, Technology & Research, Sri Ramachandra University , Porur, Chennai , India.
RNA Biol. 2018 Mar 4;15(3):320-326. doi: 10.1080/15476286.2017.1338240. Epub 2018 Feb 1.
Cancer of the head and neck are the most common cancers in India and account for 30% of all cancers. At molecular level, it could be attributed to the overexpression of growth factors like IGF1-R, EGFR, VEGF-R and deregulation of cell cycle regulators and tumor suppressors. IGF1-R is an emerging target in head and neck cancer treatment, because of its reported role in tumor development, progression and metastasis. IGF1R targeted agents are in advanced stages of clinical development. Nevertheless, these agents suffer from several disadvantages including acquired resistance and toxic side effects. Hence there is a need for developing newer agents targeting not only the receptor but also its downstream signaling. miRNAs are considered as master regulators of gene expression of multiple genes and has been widely reported to be a promising therapeutic strategy. This review discusses the present status of research in both these arenas and emphasizes the role of miRNA as a promising agent for biologic therapy.
头颈部癌症是印度最常见的癌症，占所有癌症的 30%。在分子水平上，这可能归因于生长因子如 IGF1-R、EGFR、VEGF-R 的过表达和细胞周期调节剂和肿瘤抑制因子的失调。IGF1-R 是头颈部癌症治疗的一个新兴靶点，因为它在肿瘤的发展、进展和转移中发挥作用。IGF1R 靶向药物处于临床开发的后期阶段。然而，这些药物存在多种缺点，包括获得性耐药和毒副作用。因此，需要开发新的药物，不仅针对受体，还针对其下游信号。miRNA 被认为是多个基因的基因表达的主要调控因子，并且已被广泛报道为一种很有前途的治疗策略。本文综述了这两个领域的研究现状，并强调了 miRNA 作为生物治疗有前途的药物的作用。
